[{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"PENAO Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"PENAO","moa":"||AdNT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aurigene Pharmaceutical Services \/ PENAO Pty Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Aurigene Pharmaceutical Services \/ PENAO Pty Ltd"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VIC-1911","moa":"||Aurora kinase A (AURKA)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VITRAC Therapeutics \/ University of Minnesota","highestDevelopmentStatusID":"7","companyTruncated":"VITRAC Therapeutics \/ University of Minnesota"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sio Gene Therapies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sio Gene Therapies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"National Human Genome Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sio Gene Therapies \/ National Human Genome Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ National Human Genome Research Institute"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Double Point Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Series C Financing","leadProduct":"Rapamycin","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Umoja Biopharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Double Point Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Umoja Biopharma \/ Double Point Ventures"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Aucta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aucta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ CPRIT","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ CPRIT"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Public Offering","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Insight | Biodexa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ Cancer Insight | Biodexa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Cancer Insight | Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ CPRIT","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ CPRIT"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Food and Drug Administration","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Food and Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Food and Drug Administration"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"FDA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ FDA","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ FDA"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Petrichor Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Series D Financing","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Petrichor Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Petrichor Healthcare"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Partnership","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"FDA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ FDA","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ FDA"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Whitehawk Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Whitehawk Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Divestment","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A||mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Whitehawk Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Whitehawk Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Whitehawk Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"||FK506-binding protein 1A","graph1":"Oncology","graph2":"Preclinical","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Whitehawk Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Whitehawk Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Eoc Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Collaboration","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.27000000000000002,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Eoc Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Eoc Pharma"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Foundation Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Foundation Medicine"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Private Placement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Acuta Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Acuta Capital Partners"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Aerpio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Merger","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Aerpio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Merger","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Avoro Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Private Placement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Avoro Capital","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Avoro Capital"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Insight","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emtora Biosciences \/ Cancer Insight","highestDevelopmentStatusID":"6","companyTruncated":"Emtora Biosciences \/ Cancer Insight"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emtora Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Emtora Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Basel","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University Hospital, Basel","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Basel \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Basel \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dermatology Specialties Limited Partnership","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Dermatology Specialties Limited Partnership","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dermatology Specialties Limited Partnership \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Dermatology Specialties Limited Partnership \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AgelessRx","sponsor":"University of California, Los Angeles","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgelessRx \/ University of California, Los Angeles","highestDevelopmentStatusID":"8","companyTruncated":"AgelessRx \/ University of California, Los Angeles"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"North Texas Veterans Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ North Texas Veterans Healthcare System","highestDevelopmentStatusID":"1","companyTruncated":"UT Southwestern Medical Center \/ North Texas Veterans Healthcare System"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nobelpharma \/ Undisclosed"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nobelpharma \/ Undisclosed"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nobelpharma \/ Undisclosed"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nobelpharma \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Le Bonheur Children's Hospital","sponsor":"Pfizer Inc | University of Tennessee","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Le Bonheur Children's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Le Bonheur Children's Hospital \/ Pfizer Inc | University of Tennessee","highestDevelopmentStatusID":"6","companyTruncated":"Le Bonheur Children's Hospital \/ Pfizer Inc | University of Tennessee"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Peking University First Hospital","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Peking University First Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Peking University First Hospital \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"Peking University First Hospital \/ North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"9","companyTruncated":"Peking Union Medical College Hospital \/ North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Peking Union Medical College Hospital \/ North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Beijing Municipal Science & Technology Commission | North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese SLE Treatment And Research Group \/ Beijing Municipal Science & Technology Commission | North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Chinese SLE Treatment And Research Group \/ Beijing Municipal Science & Technology Commission | North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Dongguan TT Medical","sponsor":"Peking University First Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Dongguan TT Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dongguan TT Medical \/ Peking University First Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Dongguan TT Medical \/ Peking University First Hospital"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"9","companyTruncated":"Seoul National University Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nobelpharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nobelpharma \/ Undisclosed"},{"orgOrder":0,"company":"Sinomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Sinomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinomed \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sinomed \/ Undisclosed"},{"orgOrder":0,"company":"IHF Institut f\u00fcr Herzinfarktforschung","sponsor":"OrbusNeich","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"IHF Institut f\u00fcr Herzinfarktforschung","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IHF Institut f\u00fcr Herzinfarktforschung \/ OrbusNeich","highestDevelopmentStatusID":"11","companyTruncated":"IHF Institut f\u00fcr Herzinfarktforschung \/ OrbusNeich"},{"orgOrder":0,"company":"Institut Bergoni\u00e9","sponsor":"Reliable Cancer Therapies | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Institut Bergoni\u00e9","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Bergoni\u00e9 \/ Reliable Cancer Therapies | Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Institut Bergoni\u00e9 \/ Reliable Cancer Therapies | Pfizer Inc"},{"orgOrder":0,"company":"Rare Partners srl","sponsor":"Universit\u00e0 degli Studi di Ferrara","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rare Partners srl","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rare Partners srl \/ Universit\u00e0 degli Studi di Ferrara","highestDevelopmentStatusID":"8","companyTruncated":"Rare Partners srl \/ Universit\u00e0 degli Studi di Ferrara"},{"orgOrder":0,"company":"Universit\u00e0 degli Studi di Ferrara","sponsor":"Rare Partners srl | Meyer Children's Hospital | Azienda Ospedaliero, Universitaria Pisana","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Universit\u00e0 degli Studi di Ferrara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Universit\u00e0 degli Studi di Ferrara \/ Rare Partners srl | Meyer Children's Hospital | Azienda Ospedaliero, Universitaria Pisana","highestDevelopmentStatusID":"8","companyTruncated":"Universit\u00e0 degli Studi di Ferrara \/ Rare Partners srl | Meyer Children's Hospital | Azienda Ospedaliero, Universitaria Pisana"},{"orgOrder":0,"company":"Melanoma and Skin Cancer Trials Limited","sponsor":"Monash University | University of Queensland","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Melanoma and Skin Cancer Trials Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Melanoma and Skin Cancer Trials Limited \/ Monash University | University of Queensland","highestDevelopmentStatusID":"10","companyTruncated":"Melanoma and Skin Cancer Trials Limited \/ Monash University | University of Queensland"},{"orgOrder":0,"company":"Jena University Hospital","sponsor":"Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, Jena University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Jena University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jena University Hospital \/ Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, Jena University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Jena University Hospital \/ Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, Jena University Hospital"},{"orgOrder":0,"company":"Jena University Hospital","sponsor":"Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, University Hospital Jena","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Jena University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jena University Hospital \/ Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, University Hospital Jena","highestDevelopmentStatusID":"1","companyTruncated":"Jena University Hospital \/ Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, University Hospital Jena"},{"orgOrder":0,"company":"InnoRa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"InnoRa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoRa \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"InnoRa \/ Undisclosed"},{"orgOrder":0,"company":"iVascular","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"iVascular","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iVascular \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"iVascular \/ Undisclosed"},{"orgOrder":0,"company":"Pediatric Nephrology of Alabama","sponsor":"Pfizer Inc | The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Pediatric Nephrology of Alabama","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Pediatric Nephrology of Alabama \/ Pfizer Inc | The Emmes Company, LLC","highestDevelopmentStatusID":"1","companyTruncated":"Pediatric Nephrology of Alabama \/ Pfizer Inc | The Emmes Company, LLC"},{"orgOrder":0,"company":"TransDerm, Inc.","sponsor":"Pachyonychia Congenita Project","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase I","graph3":"TransDerm, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Cream","sponsorNew":"TransDerm, Inc. \/ Pachyonychia Congenita Project","highestDevelopmentStatusID":"6","companyTruncated":"TransDerm, Inc. \/ Pachyonychia Congenita Project"},{"orgOrder":0,"company":"Stanford University","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stanford University \/ Santen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Elixir Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Elixir Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elixir Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Elixir Medical \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"National Institutes of Health | University of California, San Francisco","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unity Health Toronto \/ National Institutes of Health | University of California, San Francisco","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ National Institutes of Health | University of California, San Francisco"},{"orgOrder":0,"company":"London Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"London Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"London Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ Pfizer Inc"},{"orgOrder":0,"company":"MaineHealth","sponsor":"Desmoid Tumor Research Foundation | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MaineHealth","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaineHealth \/ Desmoid Tumor Research Foundation | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"MaineHealth \/ Desmoid Tumor Research Foundation | Pfizer Inc"},{"orgOrder":0,"company":"Narrows Institute for Biomedical Research","sponsor":"Nobelpharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase II","graph3":"Narrows Institute for Biomedical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Narrows Institute for Biomedical Research \/ Nobelpharma","highestDevelopmentStatusID":"8","companyTruncated":"Narrows Institute for Biomedical Research \/ Nobelpharma"},{"orgOrder":0,"company":"Boston Children's Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"Boston Children's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Children's Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Boston Children's Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Ohio State University","sponsor":"PTEN Research | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"Ohio State University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ohio State University \/ PTEN Research | Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Ohio State University \/ PTEN Research | Pfizer Inc"},{"orgOrder":0,"company":"University of Washington","sponsor":"Aadi Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Aadi Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ Aadi Bioscience"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma America \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Undisclosed"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma America \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Undisclosed"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma America \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Undisclosed"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma America \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Jena University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Jena University Hospital","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Jena University Hospital"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Terumo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Terumo","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Terumo"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"R3 Vascular","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"R3 Vascular","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"R3 Vascular \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"R3 Vascular \/ Undisclosed"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Series A Financing","leadProduct":"Sirolimus","moa":"||FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Undisclosed"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Undisclosed"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"The Emmes Company, LLC | Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Eye Institute \/ The Emmes Company, LLC | Santen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"National Eye Institute \/ The Emmes Company, LLC | Santen Pharmaceutical"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase III","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Cleveland Clinic \/ Pfizer Inc"},{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vascular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vascular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vascular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vascular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Neurology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Undisclosed"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Undisclosed"},{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vascular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vascular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"University College Cork","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quoin Pharmaceuticals \/ University College Cork","highestDevelopmentStatusID":"4","companyTruncated":"Quoin Pharmaceuticals \/ University College Cork"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"MedAlliance \/ Undisclosed"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Undisclosed"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Cordis","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":1.1399999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.1399999999999999,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Cordis","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Cordis"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Undisclosed"},{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Financing","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Vascular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vascular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Palvella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligand Pharmaceuticals \/ Palvella Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Ligand Pharmaceuticals \/ Palvella Therapeutics"},{"orgOrder":0,"company":"AgelessRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgelessRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgelessRx \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Financing","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Orchestra Biomed","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Orchestra Biomed \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"NEW ZEALAND","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase II","graph3":"AFT Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AFT Pharmaceuticals \/ Timber Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"AFT Pharmaceuticals \/ Timber Pharmaceuticals"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Children's Healthcare of Atlanta","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Children's Healthcare of Atlanta","highestDevelopmentStatusID":"6","companyTruncated":"Gabrail Cancer Center Research \/ Children's Healthcare of Atlanta"},{"orgOrder":0,"company":"Phillip Freeman","sponsor":"Aarhus University Hospital | Odense University Hospital | OrbusNeich | Biosensors International","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Phillip Freeman","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phillip Freeman \/ Aarhus University Hospital | Odense University Hospital | OrbusNeich | Biosensors International","highestDevelopmentStatusID":"1","companyTruncated":"Phillip Freeman \/ Aarhus University Hospital | Odense University Hospital | OrbusNeich | Biosensors International"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"||Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":1.04,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"||Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"||Lysosomal acid glucosylceramidase (GBA1)","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":1.04,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"||Lysosomal acid glucosylceramidase (GBA1)","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"||Melatonin receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Undisclosed"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"||PGRN","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"||Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Undisclosed"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"||Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Healx","sponsor":"Healx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Domatinostat","moa":"||enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Healx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healx \/ Vuja De Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Healx \/ Vuja De Sciences"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Anne Comi","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Anne Comi","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Anne Comi"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Helio Tedesco Silva Junior","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Helio Tedesco Silva Junior","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Helio Tedesco Silva Junior"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Sherif S. Farag","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Sherif S. Farag","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Sherif S. Farag"}]
Find Clinical Drug Pipeline Developments & Deals for Sirolimus
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Aucta is a global brand that creates better products from proven molecules.
